Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 95,418 shares at $25.04 ($2.4M) on 2024-04-11, disclosed to the SEC on 2024-04-15.
Scheduled sale ($2.4M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.04 | 47,709 | $1.2M | 50.0% |
| 2 | $25.04 | 47,709 | $1.2M | 50.0% |
| Total | $25.04 avg | 95,418 | $2.4M | 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |